Seegene, Inc.
Financials
Valuation Metrics
Seegene, Inc.'s Market Cap is ₩1.5T. At end of 2025 it was ₩1.2T. Ranked #243 of 2,436 in KR market (top 10%), #57 of 1,649 on KOSDAQ (top 3%), #25 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.46T KRW | KR#243/2,436 Sec#25/234 |
| Revenue | 487.37B KRW | KR#620/2,436 Sec#32/234 |
| Net Income | 54.26B KRW | KR#347/2,436 Sec#24/234 |
| Total Assets | 1.26T KRW | KR#414/2,436 Sec#22/234 |
| Net Assets | 1.02T KRW | KR#280/2,436 Sec#16/234 |
| Employees | 862 | KR#291/2,436 Sec#23/234 |
| Value | ||
| P/E | 26.90x | KR#1,213/2,436 Sec#71/234 |
| P/B | 1.43x | KR#1,747/2,436 Sec#124/234 |
| PEG | 1.34x | KR#773/2,436 Sec#48/234 |
| P/S | 3.00x | KR#2,008/2,436 Sec#126/234 |
| EV/EBITDA | 29.57x | KR#1,178/2,436 Sec#76/234 |
| FCF Yield | 7.67% | KR#727/2,436 Sec#36/234 |
| Profitability | ||
| ROE | 5.30% | KR#960/2,436 Sec#72/234 |
| ROA | 4.32% | KR#735/2,436 Sec#61/234 |
| Op. Margin | 8.88% | KR#562/2,436 Sec#51/234 |
| Revenue Growth | 11.33% | KR#875/2,436 Sec#76/234 |
| Earnings Growth | 20.12% | KR#751/2,436 Sec#48/234 |
| Financial Health | ||
| Debt Ratio | 122.71% | KR#715/2,436 Sec#87/234 |
| Total Debt | 77.09B KRW | KR#810/2,436 Sec#56/234 |
| FCF | 111.98B KRW | KR#181/2,436 Sec#9/234 |
| Cash | 257.96B KRW | KR#234/2,436 Sec#6/234 |
| Current Ratio | 4.46x | KR#350/2,436 Sec#64/234 |
| Net Debt/EBITDA | -4.18x | KR#155/2,436 Sec#4/234 |
| Dividend | ||
| Div. Yield | 3.75% | KR#510/2,436 Sec#19/234 |
| Div. Growth | 25.00% | KR#378/2,436 Sec#19/234 |
| Performance | ||
| 1Y Return | -4.28% | KR#807/2,436 Sec#59/234 |
| 1M Return | -4.77% | KR#1,378/2,436 Sec#142/234 |
| From 52W High | -14.00% | KR#93/2,436 Sec#3/234 |
| 1Y MDD | -37.84% | KR#448/2,436 Sec#33/234 |
| Trading | ||
| Volume | 239,414 shares | KR#496/2,436 Sec#50/234 |
| Foreign Own. | 18.36% | KR#252/2,436 Sec#13/234 |
| Per Share | ||
| EPS | 1,257 KRW | KR#545/2,436 Sec#37/234 |
| BPS | 22,455 KRW | KR#465/2,436 Sec#32/234 |
Company Info
Seegene, established in 2000 and headquartered in Songpa-gu, Seoul, focuses on developing gene analysis technology and reagents. The company engages in the development, manufacturing, and sales of molecular diagnostic reagents that identify disease causes through gene analysis, possessing high-multiplex syndromic quantitative PCR technology. With agencies in over 100 countries including Italy, UAE, USA, and Canada, Seegene is actively expanding its global sales network and acquired 100% of Dandi Meka's shares in 2025.